Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants

In Vitro Activity of Antibodies and Drugs against OmicronIn this study, investigators who were evaluating in vitro neutralization of omicron subvariants by monoclonal antibodies and antiviral drugs found considerable variation among the agents.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 387; no. 5; pp. 468 - 470
Main Authors Takashita, Emi, Yamayoshi, Seiya, Simon, Viviana, van Bakel, Harm, Sordillo, Emilia M., Pekosz, Andrew, Fukushi, Shuetsu, Suzuki, Tadaki, Maeda, Ken, Halfmann, Peter, Sakai-Tagawa, Yuko, Ito, Mutsumi, Watanabe, Shinji, Imai, Masaki, Hasegawa, Hideki, Kawaoka, Yoshihiro
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 04.08.2022
Subjects
Antibodies, Monoclonal - therapeutic use
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - immunology
Antiviral agents
Antiviral Agents - therapeutic use
Coronavirus
Coronaviruses
Correspondence
COVID-19
COVID-19 - immunology
COVID-19 Drug Treatment
Disease transmission
Drugs
FDA approval
Humans
Immunologic Factors - therapeutic use
Infectious Disease
Infectious diseases
Influenza
Monoclonal antibodies
Mutation
Pathogenesis
Proteins
R&D
Research & development
RNA polymerase
SARS-CoV-2 - drug effects
Severe acute respiratory syndrome coronavirus 2
Vaccine Efficacy
Viral Infections
United States > US
Japan
Online AccessGet full text

Cover

More Information
Summary:In Vitro Activity of Antibodies and Drugs against OmicronIn this study, investigators who were evaluating in vitro neutralization of omicron subvariants by monoclonal antibodies and antiviral drugs found considerable variation among the agents.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
content type line 23
Drs. Takashita and Yamayoshi contributed equally to this letter.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2207519